Computational methods and systems for magnifying cell-mediated immune response

• US 20070265787A1
• Filed: 05/25/2007
• Published: 11/15/2007
• Est. Priority Date: 08/24/2004
• Status: Abandoned Application

• Current Assignee: Searete LLC (Intellectual Ventures LLC)
• Original Assignee: Searete LLC (Intellectual Ventures LLC)
• Inventors: Jung, Edward, Wilson, Richa, Sweeney, Elizabeth, Bangera, Mahalaxmi, Myhrvold, Nathan, Wood, Lowell, Ishikawa, Muriel
• Application Number:
  US11/807,332
• Publication Number:
  US 20070265787A1
• Time in Patent Office: Days
• US Class Current: 702/19
• CPC Class Codes: A61K 39/00 Medicinal preparations containing antigens or antibodies materials for immunoassay G01N33/53
• CPC Class Codes: G16H 50/50 for simulation or modelling of medical disorders
• CPC Class Codes: G16Z 99/00 Subject matter not provided for in other main groups of this subclass
• CPC Class Codes: Y02A 90/10 Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Abstract

The present application relates, in general, to a system and/or method related to detection and/or treatment.

Claims

1. A system comprising:

at least one computer program for use with at least one computer system and wherein the computer program includes a plurality of instructions including but not limited to;

one or more instructions for suggesting at least one treatment option for at least one host, wherein the at least one treatment option is associated with modulating a predicted pattern of progression of one or more computable epitopes.

2. The system of claim 1, wherein the at least one treatment option further comprises:

at least one treatment option including at least one immune response component.

3. The system of claim 2, wherein the at least one immune response component comprises:

at least a part of one or more T cell receptor, B cell receptor, antibody, MHC molecule, CD1 molecule, adhesion molecule, cell surface molecule, cell surface receptor, chemokine, cytokine, or autocoid.

4. The system of claim 1, further comprising:

one or more instructions for suggesting delivery of at least one treatment option for at least one host.

5. The system of claim 1, further comprising:

one or more instructions for suggesting the at least one treatment option.

6. The system of claim 1, further comprising:

one or more instructions for suggesting at least one treatment option for at least one host, wherein the at least one treatment option is associated with modulating at least one immune response component.

7. The system of claim 6, wherein one or more of the at least one immune response component comprises:

at least a part of one or more of an immune cell, a lymphoid cell, a myeloid cell, a T cell, a B cell, or a Natural Killer T Cell.

8. The system of claim 1, further comprising:

one or more instructions for selecting one or more computable epitopes;

one or more instructions for predicting at least one pattern change in the one or more computable epitopes;

one or more instructions for associating the at least one pattern change in the one or more computable epitopes with at least one outcome; and

one or more instructions for designating a course of action associated with the at least one pattern change in the one or more computable epitopes.

9. The system of claim 8, further comprising:

one or more instructions for identifying at least one treatment option associated with the one or more computable epitopes.

10. A system comprising:

circuitry for suggesting at least one treatment option for at least one host, wherein the at least one treatment option is associated with modulating a predicted pattern of progression of one or more computable epitopes.

11. The system of claim 10, wherein the at least one treatment option further comprises:

at least one treatment option including at least one immune response component.

12. The system of claim 11, wherein the at least one immune response component comprises:

at least a part of one or more T cell receptor, B cell receptor, antibody, MHC molecule, CD1 molecule, adhesion molecule, cell surface molecule, cell surface receptor, chemokine, cytokine, or autocoid.

13. The system of claim 10, further comprising:

circuitry for suggesting delivery of at least one treatment option for at least one host.

14. The system of claim 10, further comprising:

circuitry for suggesting the at least one treatment option.

15. The system of claim 10, further comprising:

circuitry for suggesting at least one treatment option for at least one host, wherein the at least one treatment option is associated with modulating at least one immune response component.

16. The system of claim 15, wherein one or more of the at least one immune response component comprises:

at least a part of one or more of an immune cell, a lymphoid cell, a myeloid cell, a T cell, a B cell, or a Natural Killer T Cell.

17. The system of claim 10, further comprising:

circuitry for selecting one or more computable epitopes;

circuitry for predicting at least one pattern change in the one or more computable epitopes;

circuitry for associating the at least one pattern change in the one or more computable epitopes with at least one outcome; and

circuitry for designating a course of action associated with the at least one pattern change in the one or more computable epitopes.

18. The system of claim 17, further comprising:

circuitry for identifying at least one treatment option associated with the one or more computable epitopes.

19. A method, comprising:

suggesting at least one treatment option for at least one host, wherein the at least one treatment option is associated with modulating a predicted pattern of progression of one or more computable epitopes.

20. The method of claim 19, wherein the at least one treatment option further comprises:

at least one treatment option including at least one immune response component.

21. The method of claim 20, wherein the at least one immune response component comprises:

at least a part of one or more T cell receptor, B cell receptor, antibody, MHC molecule, CD1 molecule, adhesion molecule, cell surface molecule, cell surface receptor, chemokine, cytokine, or autocoid.

22. The method of claim 19, further comprising:

suggesting delivery of at least one treatment option for at least one host.

23. The method of claim 19, further comprising:

suggesting the at least one treatment option.

24. The method of claim 19, further comprising:

suggesting at least one treatment option for at least one host, wherein the at least one treatment option is associated with modulating at least one immune response component.

25. The method of claim 24, wherein one or more of the at least one immune response component comprises:

at least a part of one or more of an immune cell, a lymphoid cell, a myeloid cell, a T cell, a B cell, or a Natural Killer T Cell.

26. The method of claim 19, further comprising:

selecting one or more computable epitopes;

predicting at least one pattern change in the one or more computable epitopes;

associating the at least one pattern change in the one or more computable epitopes with at least one outcome; and

designating a course of action associated with the at least one pattern change in the one or more computable epitopes.

27. The method of claim 26, further comprising:

identifying at least one treatment option associated with the one or more computable epitopes.